These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 15390018)

  • 41. Sumanirole versus placebo or ropinirole for the adjunctive treatment of patients with advanced Parkinson's disease.
    Barone P; Lamb J; Ellis A; Clarke Z
    Mov Disord; 2007 Mar; 22(4):483-9. PubMed ID: 17115380
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The therapeutic effect of moclobemide, a reversible selective monoamine oxidase A inhibitor, in Parkinson's disease.
    Sternic N; Kacar A; Filipovic S; Svetel M; Kostic VS
    Clin Neuropharmacol; 1998; 21(2):93-6. PubMed ID: 9579294
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Predictors of sudden onset of sleep in Parkinson's disease.
    Körner Y; Meindorfner C; Möller JC; Stiasny-Kolster K; Haja D; Cassel W; Oertel WH; Krüger HP
    Mov Disord; 2004 Nov; 19(11):1298-305. PubMed ID: 15389999
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Bilateral impairments of skilled reach-to-eat in early Parkinson's disease patients presenting with unilateral or asymmetrical symptoms.
    Doan JB; Melvin KG; Whishaw IQ; Suchowersky O
    Behav Brain Res; 2008 Dec; 194(2):207-13. PubMed ID: 18692094
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Depression in Parkinson's disease: a double-blind, randomized, placebo-controlled pilot study of omega-3 fatty-acid supplementation.
    da Silva TM; Munhoz RP; Alvarez C; Naliwaiko K; Kiss A; Andreatini R; Ferraz AC
    J Affect Disord; 2008 Dec; 111(2-3):351-9. PubMed ID: 18485485
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Selegiline slows the progression of the symptoms of Parkinson disease.
    Pålhagen S; Heinonen E; Hägglund J; Kaugesaar T; Mäki-Ikola O; Palm R;
    Neurology; 2006 Apr; 66(8):1200-6. PubMed ID: 16540603
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The effect of pramipexole on mood and motivational symptoms in Parkinson's disease: a meta-analysis of placebo-controlled studies.
    Leentjens AF; Koester J; Fruh B; Shephard DT; Barone P; Houben JJ
    Clin Ther; 2009 Jan; 31(1):89-98. PubMed ID: 19243709
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Levodopa improves physical fatigue in Parkinson's disease: a double-blind, placebo-controlled, crossover study.
    Lou JS; Kearns G; Benice T; Oken B; Sexton G; Nutt J
    Mov Disord; 2003 Oct; 18(10):1108-14. PubMed ID: 14534913
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial.
    Goetz CG; Damier P; Hicking C; Laska E; Müller T; Olanow CW; Rascol O; Russ H
    Mov Disord; 2007 Jan; 22(2):179-86. PubMed ID: 17094088
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations.
    Hauser RA; Shulman LM; Trugman JM; Roberts JW; Mori A; Ballerini R; Sussman NM;
    Mov Disord; 2008 Nov; 23(15):2177-85. PubMed ID: 18831530
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Case studies in the advancement of Parkinson's disease.
    Frei K; Truong DD; Wolters E
    CNS Spectr; 2008 Dec; 13(12 Suppl 18):1-6. PubMed ID: 19179948
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Motor fluctuations in Parkinson's disease.
    Weiner WJ
    Rev Neurol Dis; 2006; 3(3):101-8. PubMed ID: 17047575
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Quantitative description of loss of clinical benefit following withdrawal of levodopa-carbidopa and bromocriptine in early Parkinson's disease.
    Hauser RA; Holford NH
    Mov Disord; 2002 Sep; 17(5):961-8. PubMed ID: 12360545
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Ropinirole therapy for Parkinson's disease.
    Pahwa R; Lyons KE; Hauser RA
    Expert Rev Neurother; 2004 Jul; 4(4):581-8. PubMed ID: 15853577
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Long term experience with Stalevo in Szeged, Hungary].
    Klivényi P; Vécsei L
    Ideggyogy Sz; 2009 May; 62(5-6):178-80. PubMed ID: 19579666
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A hospital-based study: risk factors in development of motor complications in 555 Parkinson's patients on levodopa therapy.
    Benbir G; Ozekmekçi S; Apaydin H; Delil S; Erginöz E
    Clin Neurol Neurosurg; 2006 Dec; 108(8):726-32. PubMed ID: 16564615
    [TBL] [Abstract][Full Text] [Related]  

  • 57. High-dose treatment with pergolide in Parkinson's disease patients with motor fluctuations and dyskinesias.
    Storch A; Trenkwalder C; Oehlwein C; Winkelmann J; Polzer U; Hundemer HP; Schwarz J
    Parkinsonism Relat Disord; 2005 Sep; 11(6):393-8. PubMed ID: 15993640
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease.
    Pahwa R; Stacy MA; Factor SA; Lyons KE; Stocchi F; Hersh BP; Elmer LW; Truong DD; Earl NL;
    Neurology; 2007 Apr; 68(14):1108-15. PubMed ID: 17404192
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Improvements in motor and non-motor symptoms in parkinson patients under ropinirole therapy].
    Buchwald B; Angersbach D; Jost WH
    Fortschr Neurol Psychiatr; 2007 Apr; 75(4):236-41. PubMed ID: 17427044
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Modulatory effect of clozapine on levodopa response in Parkinson's disease: a preliminary study.
    Arevalo GJ; Gershanik OS
    Mov Disord; 1993 Jul; 8(3):349-54. PubMed ID: 8341300
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.